+ND Capital
Venture capitalWoodside · Seed–Late Stage · 17 people tracked
Also known as NANODIMENSION AG · NANODIMENSION, INC.
Investment thesis
+ND Capital invests in companies built on breakthroughs at the nanoscale, applying deep scientific expertise to distinguish genuine innovation from speculation. Founded on the conviction that significant technological advances would emerge from nanotechnology, the firm combines European scientific roots with a strong presence in the US venture ecosystem, particularly Boston and Silicon Valley, where it identifies compelling investment opportunities across energy, materials, therapeutics, and advanced technology.
Source: firm website, verified Aug 25, 2026.
Team · 17 people
from the firm's website & public directories
Founder mafia
2 people who came through +ND Capital went on to found or lead other companies.
What they invest in
from 27 of 33 portfolio companiesBiotech ×23Healthtech ×13Deep Tech ×10Medical Devices ×7AI & Machine Learning ×6Digital Health ×3Hardware ×3Semiconductors ×3
HQs:United States×14Switzerland×3Denmark×2United Kingdom×1
Who they back
founder profiles across 16 portfolio companiesFounding team size:solo founder×62 founders×53 founders×34+ founders×2
Investments · 33 tracked
founders shown can be your intro pathBy year:2026 · 12024 · 12022 · 12021 · 12019 · 12016 · 16 dated
Twist Bioscience develops a silicon-based synthetic DNA manufacturing platform that produces high-quality DNA, genes, and NGS reagents for customers in medicine, agriculture, and industrial chemicals.
BiotechDeep TechSemiconductorsSouth San Francisco, US
Emily Marine Leproust(Executive Officer, Director, Promoter)William Charles Banyai(Executive Officer, Director, Promoter)Bill James Peck(Executive Officer, Promoter)Emily Leproust(Founder)in
BoardKeith Crandell(Director)Paul Conley(Director)in
Co-investors3E Bioventures CapitalARCH Venture PartnersAsset Management CompanyBay City CapitalBlack Opal VenturesDentsu Ventures+7 more
Emulate builds Organ-on-a-Chip systems, including platforms, consumables, and pre-assembled BioKits with validated human cell models, to support drug discovery research.
BiotechDeep TechHealthtech
Donald Ingber(Scientific Founder, Board Member, Scientific Advisory Board Chairman)Daniel Levner(Co-Founder & CTO)Jim Corbett(CEO, Board Member)Lorna Ewart(Chief Scientific Officer)
Co-investorsNorthpond VenturesAlwyn CapitalFourth RealmStray Dog CapitalOS FundStarlight Ventures
Notify develops pharmaceutical treatments for women with diminished ovarian reserves by targeting dormant follicle activation through NRF2 pathway modulation.
BiotechDigital HealthFemTechHealthtechMedical DevicesAarhus, DK
Karin Lykke-Hartmann(Chief Executive Officer & Founder)
PulseSight Therapeutics develops non-viral, plasmid-based gene therapies delivered via a proprietary electro-transfection system into the ciliary muscle to treat severe retinal diseases causing blindness.
BiotechHealthtechMedical Devices
Co-investorsPureos Bioventures
Vandria is a pharmaceutical development company focused on translating scientific innovation into first-in-class therapeutics.
BiotechHealthtechLongevityMedical DevicesLausanne, CH
Patrick Aebischer(Co-founder)Pénélope Andreux(Head of Research (mitochondrial research and development))Klaus Dugi(Chief Medical Officer / Medical Leadership)Peter(Business Development & Entrepreneurship Leadership)Leila(Operations Leadership)Anke Post(Chief Medical Officer / Neuroscience Leadership)
Co-investorsDolby Family Ventures
AIRNA develops genetic medicines that use ADAR, a naturally occurring human protein, to precisely edit RNA and treat genetic diseases without permanently modifying DNA.
AI & Machine LearningBiotechDeep TechHealthtech
Kris ElveruminTodd Bazemore(Chief Executive Officer)
BoardRodger Novak(Chair)
Co-investorsARCH Venture PartnersForbionVenrockFast Track InitiativeNextech InvestNovalis LifeSciences+2 more
BiotechSouth San Francisco, US
Wendye Robbins(Executive Officer, Director)
BoardLuke Evnin(Director)inCameron Wheeler(Director)Elaine Jones(Director)William Slattery(Director)
Board seatPeter Van Vlasselaer· per SEC Form D · $50M raise · filed Oct 2019
Co-investorsBay City CapitalOUP (Osage University Partners)Pfizer Venture InvestmentsMPM BioImpact
BiotechNew York, US
Masoud Tavazoie(Chief Scientific Officer)David Darst(Chief Operating Officer)Isabel Kurth(Vice President - Research)
BoardShahram Seyedin-Noor(Executive Chairman)Nancy Chang(Director)
Board seatPeter Van Vlasselaer· per SEC Form D · $11M raise · filed Feb 2021
Co-investorsSofinnova Partners
ALLInBio develops a precision immunology approach to identify and treat patients genetically predisposed to rapid progression of chronic inflammatory diseases.
BiotechHealthtechMedical Devices
Co-investorsArtis Ventures
Co-investorsSanofi VenturesSolasta Ventures
Co-investorsSQN Venture Partners, LLC
Amazentis is a Swiss longevity-biotech company that developed Mitopure, a proprietary high-purity form of the postbiotic Urolithin A shown in human trials to support mitochondrial health via mitophagy.
BiotechLongevityWellness & FitnessLausanne, CH
Co-investorsBold Capital Partners
Arc Therapeutics is a stealth-stage biopharmaceutical company developing medicines for central nervous system (CNS) conditions with high unmet medical needs.
BiotechHealthtech
Co-investorsV-Bio Ventures
Constructive Bio is a biotechnology company that rewrites the genetic code to give cells access to non-canonical amino acid building blocks, expanding the range of proteins that can be designed, engineered, and manufactured.
BiotechDeep TechNew Materials
Jason Chin(Professor)
Co-investorsAmadeus Capital PartnersFine Structures VenturesGENERAL INCEPTIONLongeVCOMX VenturesPaladin Capital Group+2 more
Crocus Technology, now part of Allegro MicroSystems, develops XtremeSense TMR (Tunnel Magnetoresistance) magnetic sensing technology used in integrated current and position sensor ICs.
Co-investorsVentechVentech China
Cytoki Pharma is a clinical-stage biotechnology company developing IL-22-based medicines for metabolic diseases such as obesity and type 2 diabetes, and conditions involving epithelial injury like inflammatory bowel disease.
BiotechHealthtechVærløse, DK
Rasmus Jorgensen(Founder)
Co-investorsYsios CapitalSeventure Partners
H55 develops certified electric propulsion systems and energy storage solutions for aviation, enabling aircraft manufacturers to transition to electric flight.
CleantechEnergyHardwareMobility & TransportationSion, CH
André Borschberg(Co-Founder and Executive Chairman)
Co-investorsACE & Company
HAYA Therapeutics develops precision RNA medicines that target long non-coding RNAs (lncRNAs) in the regulatory genome to reprogram disease at the level of cell state, with a lead program in cardiac fibrosis and work in obesity and metabolic disease.
AI & Machine LearningBiotechDeep TechHealthtech
Samir Ounzain(Chief Executive Officer (CEO) & Co-founder)Daniel Blessing(Chief Scientific Officer (CSO) & Co-founder)inRichard Law(Chief Business Officer (CBO))inEric Adam(Chief Operating Officer (COO))inJordan Shin(Chief Medical Officer (CMO))inJérôme Andries(Chief Financial Officer (CFO))in
Co-investorsBroadview VenturesSofinnova PartnersApollo Health Ventures4see Ventures
BiotechBoulder, US
Michael Graige(Executive Officer)Ron McGrath(Executive Officer)Sri Kosaraju(Executive Officer, Director)Dianna L. DeVore(Executive Officer)
BoardRoger Wyse(Director)inBryan Roberts(Director)
Co-investorsForesite CapitaliGlobe PartnersKorysOak HC/FTOMX VenturesPaladin Capital Group+3 more
Lightcast develops a single-cell functional analysis platform that uses droplet-based technology to profile cell function, biomolecule secretion, cell-cell interactions, and targeted cell killing at scale.
BiotechDeep TechHealthtech
Co-investorsIllumina VenturesLongwall Venture Partners LLPM VenturesOMX VenturesARCH Venture Partners
Manus Bio uses industrial biotechnology and engineered microbial cell factories to produce "BioAlternatives" — sustainable versions of molecules normally sourced from petrochemicals, agriculture, or animal husbandry — and offers a scale-up platform covering cell factory design through biomanufacturing.
BiotechFoodTechNew MaterialsAugusta, US
Ajikumar Parayil(Executive Officer, Director)inAji Parayil(Co-founder)Greg Stephanopoulos(Co-founder)Gregory Stephanopoulos(Director)
BoardJason Whaley(Director)inCarsten Boers(Director)in
Co-investorsCivilization Ventures Management, LlcEnergy Impact PartnersLiebenthal VenturesNelstone VenturesNXT VenturesPrefix Capital+2 more
RNA therapeutics company with a chip-based mRNA manufacturing platform; acquired by Medici Therapeutics in November 2025.
BiotechEmeryville, US
Igor Khandros(Executive Officer, Director)
Co-investorsARCH Venture PartnersBluebird Ventures
Octant is a therapeutics company that develops small molecule drugs to treat protein misfolding diseases.
AI & Machine LearningBiotechDeep TechMedical DevicesEmeryville, US
Sri Kosuri(Co-founder)inRamsey Homsany(Founder)in
Co-investorsAndreessen Horowitz8VCCarbon SiliconCatalio Capital Management, LPFifty YearsFlucas Ventures+5 more
Orca Bio develops allogeneic T-cell immunotherapies for high-risk blood cancers including acute myeloid leukemia, acute lymphocytic leukemia, and myelodysplastic syndrome.
BiotechDigital HealthHealthtechMedical DevicesCalifornia, US
Jeroen(Co-founder and President)Ivan Dimov(Executive Officer, Director)inNathaniel Fernhoff(Executive Officer, Director)in
BoardAlex Kolicich(Director)inJonathan MacQuitty(Director)in
Co-investors8VCDCVC (Data Collective)Felicis VenturesLightspeed Venture PartnersSeraph Group
Partillion generates cell-cell interaction data using Nanovials that co-localize cells in defined microenvironments to measure signaling, activation, binding, and other responses, with live-cell recovery via standard flow cytometry.
AI & Machine LearningBiotechDeep TechLos Angeles, US
Joseph de Rutte(Executive Officer, Director)Dino Di Carlo(Director)Joe de Rutte(Founder)inEric Moessinger(Director)
BoardPaul Conley(Director)
Co-investorsGENERAL INCEPTIONPaladin Capital GroupVertical Venture Partners
Serotiny designs cell therapies using custom software and lab techniques that allow it to design and test up to 10,000 therapeutic genes at once, aiming to speed up the discovery of treatments for cancers such as multiple myeloma, prostate cancer and lung cancer.
AI & Machine LearningBiotechHealthtechSan Francisco, US
Justin Farlow(Co-founder)Colin Farlow(Co-founder)Eric Moessinger(Director)
SiMa.ai designs silicon and software to enable machine learning inference at the edge, deployed in industrial, automotive, and autonomous systems rather than cloud environments.
AI & Machine LearningDeep TechHardwareSemiconductorsSan Jose, US
Krishna Rangasayee(Founder & CEO)in
Co-investorsAmplify PartnersWing
SPARK Microsystems develops ultra-wideband (UWB) wireless connectivity technology for applications including Physical AI, XR, audio, gaming, human interface, and IoT devices.
Deep TechHardwareIoTSemiconductors
Co-investorsSilicon CatalystCycle Capital
BiotechWatertown, US
Omid Farokhzad(Director)inRobert S. Langer, Jr.(Director)Omid C. Farokhzad(Director)inRobert S. Langer(Director)Andrew J. Fromkin(Executive Officer, Director)Leila Alland(Executive Officer)in
Co-investorsKendall Capital Partners
Visby offers an FDA-authorized at-home PCR test kit for women's sexual health that detects chlamydia, gonorrhea, and trichomoniasis from a single swab, delivering private results via a mobile app in about 30 minutes with included same-day telehealth for positive results.
ConsumerDigital HealthFemTechHealthtechMedical DevicesTokyo, US
Adam de la Zerda(Founder)in
Co-investors1809 CapitalAmplify PartnersArtiman VenturesG Vision CapitalKhosla VenturesSeraph Group+5 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 2
IPOs and acquisitions across the tracked portfolioAlumniNYSE: AZNTwist BioscienceNASDAQ: TWST
Portfolio news
latest coverage across their companies
Lightcast · kb.lightcast.io · Jul 2, 2026
SPARK Microsystems · finance.yahoo.com · May 14, 2026
Inscripta · chiefhealthcareexecutive.com · Jan 8, 2026
Octant Bio · salestools.io · Oct 23, 2025
Constructive Bio · nature.com · Oct 20, 2025
Nutcracker Therapeutics · businessmodelcanvastemplate.com · Jul 11, 2025
Frequently asked questions
- How many investments has +ND Capital made?
- +ND Capital has 30 tracked investments, 2 of which have exited via acquisition or IPO, including 2 dated in the last 24 months.
- What stage does +ND Capital invest at?
- +ND Capital invests at the Seed, Series A, Series B, Series C, Late Stage stages.
- What is +ND Capital's typical check size?
- +ND Capital typically writes checks of $540K – $5.4M.
- What sectors does +ND Capital focus on?
- +ND Capital focuses on Biotech, Deep Tech, Energy, Hardware, Healthtech, New Materials, Semiconductors.
- Where is +ND Capital located?
- +ND Capital is headquartered in Woodside, CH.
- Does +ND Capital lead rounds?
- Yes, +ND Capital leads investment rounds.
- Who does +ND Capital co-invest with?
- +ND Capital most often shares deals with ARCH Venture Partners, OMX Ventures, Paladin Capital Group, among 68 tracked co-investors.
Co-investors · 15
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
Paladin Capital Group invests in early stage and growth companies developing cyber, AI and deep technologies that address security and resilience needs for commercial and government customers.
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
Venrock is a venture capital firm investing across technology and healthcare, backing companies in fintech, developer infrastructure, life sciences, therapeutics, semiconductors, and consumer products.
Seventure Partners is a European venture capital firm, founded in 1997 and a subsidiary of Natixis Investment Managers, investing in digital technologies and life sciences companies with strong growth potential.
Ysios Capital is a life sciences investor that finances innovative biotech companies worldwide, providing resources to develop novel therapies for indications with high unmet medical needs.
Apollo Health Ventures is a biotech-focused investor that combines traditional funding with venture building to back transformative healthcare and longevity companies in Europe and the US.
Illumina Ventures is a venture investor focused on genomics and precision health, aiming to advance innovation and impact in human health.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
▶3 more co-investors
Firms observed investing alongside +ND Capital, from public investor directories. Shared companies are the overlap with +ND Capital's recorded portfolio.
Similar investors
EDBI is the investment platform of Singapore's Economic Development Board and Enterprise Singapore, focusing on high-growth technology companies expanding into Singapore and Asia.
Safar Partners is an early-stage technology investment firm that backs startups spun out of leading research universities, primarily MIT, Harvard, and the University of Rochester.
South China Venture Capital (中南创投基金), established in 2008, manages multiple RMB- and USD-denominated venture capital funds focused on technology innovation.
VantagePoint Capital Partners is a global venture investor backing companies from startup through scale-up, with a particular focus on energy innovation and efficiency.
Hercules Capital is a business development company specializing in venture lending, providing flexible debt and equity capital to venture-backed companies in the life sciences and technology sectors.